Erythropoietin reduces lipopolysaccharide-induced cell damage and midkine secretion in U937 human histiocytic lymphoma cells

YAZIHAN N., Karakurt O., Ataoglu H.

ADVANCES IN THERAPY, cilt.25, sa.5, ss.502-514, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 5
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1007/s12325-008-0055-5
  • Dergi Adı: ADVANCES IN THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.502-514
  • Anahtar Kelimeler: erythropoietin, lipopolysaccharide, midkine, tumour necrosis factor alpha, interleukin-6, HEPARIN-BINDING CYTOKINE, CEREBRAL MALARIA, GROWTH-FACTOR, RECEPTOR, MICE, APOPTOSIS, SURVIVAL, DEATH
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: Erythropoietin (EPO) is a haematopoietic stimulatory protein that is used to treat anaemia in patients on dialysis. In addition, EPO has been shown to have anti-inflammatory properties, which may be important as dialysis patients tend to exist within a chronic, low-grade inflammatory state, and tend to be more susceptible to infections. It has been suggested that EPO has direct immunomodulatory potency on monocytes/macrophages.